Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. (October 2022) - Mascarella, M.; Olonisakin, T.; Rumde, P.; Vendra, V.; Nance, M.; Kim, S.; Kubik, M.; Sridharan, S.; Ferris, R.; Moon, F.; Clayburgh, D.; Ohr, J.; et al.